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Abstract 
The regression effect gives a misleading impression of the relation 
between drug or treatment effect and baseline measurement. We propose 
a method of adjusting for regression effect and a corresponding test 
for differential drug effect. These are illustrated using .blood 
pressure data. 
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1. Introduction 
A common method for assessing the effect of a dr~g or other treatment 
on a measurement is to compare baseline with postdrug, using each patient 
or subject as its own control. A test of the null hypothesis that the 
average difference is zero is carried out using a Student t test or a 
Wilcoxon signed-rank test. For efficacy measures a maximal effect may 
be desirable and for safety measures a minimal effect is desirable; while 
our methods apply to both, some of our discussion is presented in terms of 
·the latter for convenience. In particular, our examples deal with blood 
pressure changes associated with an antiarrhythmic agent. 
If there is an overall increase, say, between pre- and postdrug then 
the effect may be less important if the increase is less for patients with 
high baselines than for those with low baselines. One might test fo~ 
differential effect of the drug by regressing change from baseline on base-
line. In a similar vein, one might give average changes from baseline for 
low, middle, and high baseline values. One might feel that the drug is 
safer if the average increase for high baselines is less than it is overall. 
But such analyses are incorrect. 
The problem is that an apparent differential effect may simply reflect 
a regression effect. Even if there is no :drug effect whatever, patients 
with high baselines will tend to have lower second readings--these 
second readings will tend to be higher than average but lower than the 
corresponding baselines. In this paper we assume the joint distribution 
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of the two readings (or a suitable transformation) is normal and address 
the problem of removing the regression effect when the drug effect is 
additive. Based on this analysis we propose a simple test for differential 
drug effect. Examples are given in Section 4. 
2. Regression and differential effect 
Let x1 denote baseline and x2 the corresponding postdrug measurement. 
Assuming normality: 
For the before/after data we have in mind the correlation coefficient p 
· will usually be positive, but such an assumption is not necessary in 
what follows. 
If there is no drug effect (or confounding time effect) then x1 and 
x2 will have the same marginal distributions: A= 0 and a1 = a2• If the 
drug affects all patients additively and equally then Ar/ 0 and, again, 
a 1 = a2 • While there is no real differential drug effect in either case, there 
is an apparent one. 
To see this, consider the joint distribution of baseline and change 
from baseline when there is an additive effect and a1 = a2 = a: 
1 
p-1 
p-1 )) 
2(1-p) • 
The regression function of x2- x1 on x1 is 
E(X2 - xl lxl) = A - (1 - p )(Xl - µ). 
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The regression effect has an obvious impact on change from baseline; 
for example, subjects with large baselines (X1) have smaller than average 
change from baseline. The regression effect can be removed (for purposes 
of plotting as well as further analysis) by considering 
Y = x2 - xl + (1 - P )(Xl - lJ) = x2 - µ - P <x1 - JJ) 
versus x1• Since E(YIX1)=8 when there is no differential drug effect, a 
nonzero slope of the regression of Yon x1 indicates a genuine differential 
effect. 
In the general model with a1 and a2 ~rbitrary, 
E cx2 - x1 I x1) = 8 + (1 - Pe )(x1 - µ), 
where .. ·e = a/a1• Also, 
E(Y (x1) = 8 +p (8 - l)(X1 - µ). 
The null hypothesis of no differential drug effect and its alternative 
are 
H0 : a 1 = a 2 , H1 : a 1 I a 2 • 
A differential effect--if one is present--is negative or positive corres-
ponding to the sign of p ( e - 1) • 
Figure 1 illustrates this phenomenon with 8 > 0 and p > O; ellipses 
of constant bivariate normal density are shown. In Figure lA there is no 
differential drug effect, e = 1. In Figure lB there is a negative differential 
effect, 8<1; large baselines are increased less than small baselines. In 
Figure lC there is a positive differential effect, 8 > 1; the figure was 
-1 drawn with 8 = p which means there is apparently no differential effect in 
comparing x2 - x1 with x1-it is masked by the regression effect. 
[Figure 1 about here.] 
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3. Testing for differential effect 
The maximwn likelihood estimates of o2 and p under u0 are 
2 2 
where s1 , s2 , and rare usual unrestricted maximum likelihood estimates 
2 2 
of o1 ,o2 , and p. The likelihood ratio test of u0 vs. H1 is 
Reject if s1 s2 I 
s2 - 5i°" . / 1-r2 > K. 
The null distribution of the test statistic is independent of p; in fact 
(1) T = ln="2 (s1 - s2)~ //. -2 
2 s2 sl 1/ 1- r 
has a Student t distribution with n-2 degrees of freedom where n is the 
· sample size. 
To see this, 
Testing o1 = o2 is the same as testing Pu U = O. Since u 1 and u 2 are p 2 
jointly normal, the likelihood ratio test of Pu U = 0 is the usual t 
1' 2 
test based on 
T = /n-2 ru U / /1 - ri U 
1' 2 l' 2 
which is algebraically equal to T as defined in (1). This test 
was derived originally by Pitman (1939) and Morgan (1939). 
To summarize, the presence of an additive drug effect can be tested 
with the usual paired t test (assuming normality is not violated in an 
important way). The possibility that the drug affects patients differentially, 
depending on their baselines, can be tested using (1). 
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4. Examples 
The method presented above is illustrated using diastolic blood 
pressure data from a recent multicenter clinical trial. (The Flecainide-
Quinidine Research Group 1983.) This trial employed a randomized, 
double-blind design to compare two antiarrhythmic agen~s, flecainide 
acetate and quinidine sulfate, on the basis of efficacy and safety. 
There were seven days of placebo, after which baseline readings were 
taken, 14 days of active drug, and then seven days of placebo washout. 
[Figures 2 to 5 about here.] 
The washout data, using patients randomized to flecainide, provide 
an example in which there should be neither an additive nor a differential 
effect. Figure 2 shows the plot of change from baseline at washout vs 
. 
baseline (X2 - x1 vs x1). This clearly shows the regression effect. 
Figure 3 is the plot of these data after removing the regression effect 
(Y vs x1), showing that there is no differential effect. The t test for 
additive effect gives T = 0.80, which is not significant. To test for 
differential effect, the t test described above gives T = 0.55, which is 
not significant. 
The diastolic blood pressure data while on flecainide provide an 
example in which there may be an additive and also a differential effect. 
Figure 4 is the plot of change from baseline vs baseline (X2 - x1 vs x1). 
There seems to be a small additive effect (A= 3.1 mmHg) for which T = 3.50 
(very significant) and an apparent negative differential effect. Figure 5 
shows the data after the regression effect has been removed. The t statistic 
for differential effect is T = 0.84, which is not significant. Evidently, 
the drug affects all patients in this population equally and additively. 
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While a casual analysis leads to one conclusion, a correct analysis leads 
to quite another. 
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Figure 1. Bivariate normal contours showing differential drug effect. 
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